New drug MAR002 takes first step toward treating acromegaly

NCT ID NCT07195175

Recruiting now Disease control Sponsor: Marea Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAR002
What this could lead to: If safe, this could lead to a new treatment option for acromegaly, a condition caused by too much growth hormone.
What could go wrong: This is a very early Phase 1 trial in healthy men, not patients. It only tests safety and dosing, not whether it works for acromegaly. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY

Contacts and locations

Locations

Marea Site
RECRUITING

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.